Posted in

2019

Congratulations to Dr. Asirvatham and Dr. Jorns

I am pleased to inform you that your short course proposal, entitled “Pathologic Assessment of Axillary Lymph Nodes in Breast Cancer and Implications for Current Clinical Management”, has been accepted by the Education Committee. The course will begin a three-year term at the 2021 Annual Meeting in Baltimore, MD. Presentation at future meetings (2022 and 2023) is…

The University of Florida Sets a Record at Osler!

Pathologists The Osler Institute has over thirty years of experience in preparing physicians for their board examinations. This year, the University of Florida will have seven pathologists participating in the Osler Pathology Course.  These include Dr. Asirvatham, Dr. Kresak, Dr. Shenoy, Dr. Winter, Dr. Feely, Dr.

You’re Invited: Dr. Mark Atkinson UF COM Wall of Fame

We would like to share the wonderful news that Mark Atkinson, PhD’88 has been selected by the Medical Alumni Board to be added this year to the UF College of Medicine Wall of Fame along with Christopher Broder, PhD’89. We hope you will be able to join us for the…

UFDI 2019 Second Quarter Update

Stay up -to-date on the latest diabetes news and happenings in the University of Florida community with this newsletter. UFDI 2019 Second Quarter Update …

Laying the Groundwork

A field trip to UF Health introduces middle and high school girls to medicine. August 5, 2019—Formative experiences in childhood and young adulthood can often spark a lifelong passion and even influence one’s professional future. One UF College of Medicine faculty organization aimed to inspire young minds toward a…

The University of Florida Health Cancer Center has awarded a 2019 GI, Lung & Prostate Cancer Research Pilot Project to Dr. Maria Zajac-Kaye, Department of Anatomy and Cell Biology and Dr. Timothy Garrett, Department of Pathology, Immunology, and Laboratory Medicine

Title: Targeting nucleotide synthesis and defining metabolic pathways in Kras– driven pancreatic cancer Pancreatic cancer remains a lethal, RAS-driven cancer with an incidence that has increased 60% over the past decade. Current chemotherapeutic regimens fail to meaningfully extend survival and result in drug resistance. RAS is a key initiator in…